S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
pixel
Log in
NYSE:LH

Laboratory Co. of America Competitors

$243.65
+2.15 (+0.89 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$241.79
Now: $243.65
$246.92
50-Day Range
$214.81
MA: $231.56
$247.15
52-Week Range
$98.02
Now: $243.65
$252.45
Volume765,307 shs
Average Volume802,608 shs
Market Capitalization$23.73 billion
P/E Ratio28.36
Dividend YieldN/A
Beta1.09

Competitors

Laboratory Co. of America (NYSE:LH) Vs. DGX, DVA, AMED, RCM, CHE, and LHCG

Should you be buying LH stock or one of its competitors? Companies in the sub-industry of "health care services" are considered alternatives and competitors to Laboratory Co. of America, including Quest Diagnostics (DGX), DaVita (DVA), Amedisys (AMED), R1 RCM (RCM), Chemed (CHE), and LHC Group (LHCG).

Laboratory Co. of America (NYSE:LH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Insider & Institutional Ownership

89.3% of Laboratory Co. of America shares are held by institutional investors. Comparatively, 85.7% of Quest Diagnostics shares are held by institutional investors. 0.7% of Laboratory Co. of America shares are held by company insiders. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares Laboratory Co. of America and Quest Diagnostics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion2.05$823.80 million$11.3221.52
Quest Diagnostics$7.73 billion2.05$858 million$6.5618.07

Quest Diagnostics has lower revenue, but higher earnings than Laboratory Co. of America. Quest Diagnostics is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations for Laboratory Co. of America and Quest Diagnostics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011402.93
Quest Diagnostics09602.40

Laboratory Co. of America currently has a consensus price target of $235.4667, suggesting a potential downside of 3.36%. Quest Diagnostics has a consensus price target of $129.00, suggesting a potential upside of 8.81%. Given Quest Diagnostics' higher probable upside, analysts plainly believe Quest Diagnostics is more favorable than Laboratory Co. of America.

Risk & Volatility

Laboratory Co. of America has a beta of 1.09, indicating that its share price is 9% more volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 1.07, indicating that its share price is 7% more volatile than the S&P 500.

Profitability

This table compares Laboratory Co. of America and Quest Diagnostics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
Quest Diagnostics13.22%19.23%8.77%

Summary

Laboratory Co. of America beats Quest Diagnostics on 10 of the 14 factors compared between the two stocks.

DaVita (NYSE:DVA) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Valuation & Earnings

This table compares DaVita and Laboratory Co. of America's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
DaVita$11.39 billion0.99$810.98 million$5.4019.17
Laboratory Co. of America$11.55 billion2.05$823.80 million$11.3221.52

Laboratory Co. of America has higher revenue and earnings than DaVita. DaVita is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for DaVita and Laboratory Co. of America, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
DaVita04102.20
Laboratory Co. of America011402.93

DaVita currently has a consensus price target of $116.40, indicating a potential upside of 12.44%. Laboratory Co. of America has a consensus price target of $235.4667, indicating a potential downside of 3.36%. Given DaVita's higher possible upside, equities research analysts plainly believe DaVita is more favorable than Laboratory Co. of America.

Insider & Institutional Ownership

91.7% of DaVita shares are owned by institutional investors. Comparatively, 89.3% of Laboratory Co. of America shares are owned by institutional investors. 1.0% of DaVita shares are owned by company insiders. Comparatively, 0.7% of Laboratory Co. of America shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares DaVita and Laboratory Co. of America's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
DaVita7.32%43.99%5.27%
Laboratory Co. of America6.79%21.05%8.83%

Risk and Volatility

DaVita has a beta of 1.3, meaning that its stock price is 30% more volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500.

Summary

Laboratory Co. of America beats DaVita on 8 of the 14 factors compared between the two stocks.

Amedisys (NASDAQ:AMED) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Profitability

This table compares Amedisys and Laboratory Co. of America's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Amedisys8.22%26.41%12.43%
Laboratory Co. of America6.79%21.05%8.83%

Analyst Recommendations

This is a summary of recent ratings and target prices for Amedisys and Laboratory Co. of America, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Amedisys03902.75
Laboratory Co. of America011402.93

Amedisys currently has a consensus target price of $274.4615, indicating a potential upside of 8.68%. Laboratory Co. of America has a consensus target price of $235.4667, indicating a potential downside of 3.36%. Given Amedisys' higher probable upside, equities analysts clearly believe Amedisys is more favorable than Laboratory Co. of America.

Risk & Volatility

Amedisys has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.09, meaning that its share price is 9% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amedisys and Laboratory Co. of America's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Amedisys$1.96 billion4.24$126.83 million$4.4057.39
Laboratory Co. of America$11.55 billion2.05$823.80 million$11.3221.52

Laboratory Co. of America has higher revenue and earnings than Amedisys. Laboratory Co. of America is trading at a lower price-to-earnings ratio than Amedisys, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

85.9% of Amedisys shares are owned by institutional investors. Comparatively, 89.3% of Laboratory Co. of America shares are owned by institutional investors. 2.8% of Amedisys shares are owned by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Laboratory Co. of America (NYSE:LH) and R1 RCM (NASDAQ:RCM) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Analyst Recommendations

This is a summary of recent ratings for Laboratory Co. of America and R1 RCM, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011402.93
R1 RCM00503.00

Laboratory Co. of America presently has a consensus target price of $235.4667, suggesting a potential downside of 3.36%. R1 RCM has a consensus target price of $28.60, suggesting a potential upside of 1.94%. Given R1 RCM's stronger consensus rating and higher probable upside, analysts clearly believe R1 RCM is more favorable than Laboratory Co. of America.

Risk and Volatility

Laboratory Co. of America has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, R1 RCM has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.

Profitability

This table compares Laboratory Co. of America and R1 RCM's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
R1 RCM3.69%117.07%4.39%

Institutional and Insider Ownership

89.3% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 81.2% of R1 RCM shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by company insiders. Comparatively, 59.4% of R1 RCM shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Earnings & Valuation

This table compares Laboratory Co. of America and R1 RCM's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion2.05$823.80 million$11.3221.52
R1 RCM$1.19 billion6.18$12 million($0.08)-350.69

Laboratory Co. of America has higher revenue and earnings than R1 RCM. R1 RCM is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks.

Summary

Laboratory Co. of America beats R1 RCM on 8 of the 14 factors compared between the two stocks.

Chemed (NYSE:CHE) and Laboratory Co. of America (NYSE:LH) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk and institutional ownership.

Earnings and Valuation

This table compares Chemed and Laboratory Co. of America's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chemed$1.94 billion3.64$219.92 million$13.9531.68
Laboratory Co. of America$11.55 billion2.05$823.80 million$11.3221.52

Laboratory Co. of America has higher revenue and earnings than Chemed. Laboratory Co. of America is trading at a lower price-to-earnings ratio than Chemed, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent recommendations for Chemed and Laboratory Co. of America, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chemed00203.00
Laboratory Co. of America011402.93

Chemed presently has a consensus target price of $557.50, indicating a potential upside of 26.14%. Laboratory Co. of America has a consensus target price of $235.4667, indicating a potential downside of 3.36%. Given Chemed's stronger consensus rating and higher possible upside, research analysts clearly believe Chemed is more favorable than Laboratory Co. of America.

Profitability

This table compares Chemed and Laboratory Co. of America's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chemed13.11%38.13%21.70%
Laboratory Co. of America6.79%21.05%8.83%

Volatility & Risk

Chemed has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Laboratory Co. of America has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500.

Insider & Institutional Ownership

86.0% of Chemed shares are held by institutional investors. Comparatively, 89.3% of Laboratory Co. of America shares are held by institutional investors. 4.0% of Chemed shares are held by insiders. Comparatively, 0.7% of Laboratory Co. of America shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Chemed beats Laboratory Co. of America on 8 of the 14 factors compared between the two stocks.

Laboratory Co. of America (NYSE:LH) and LHC Group (NASDAQ:LHCG) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares Laboratory Co. of America and LHC Group's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Laboratory Co. of America6.79%21.05%8.83%
LHC Group5.00%9.71%6.51%

Analyst Ratings

This is a summary of recent ratings and price targets for Laboratory Co. of America and LHC Group, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Laboratory Co. of America011402.93
LHC Group01702.88

Laboratory Co. of America presently has a consensus price target of $235.4667, suggesting a potential downside of 3.36%. LHC Group has a consensus price target of $227.7778, suggesting a potential upside of 24.51%. Given LHC Group's higher probable upside, analysts plainly believe LHC Group is more favorable than Laboratory Co. of America.

Volatility & Risk

Laboratory Co. of America has a beta of 1.09, meaning that its stock price is 9% more volatile than the S&P 500. Comparatively, LHC Group has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Insider and Institutional Ownership

89.3% of Laboratory Co. of America shares are owned by institutional investors. Comparatively, 91.8% of LHC Group shares are owned by institutional investors. 0.7% of Laboratory Co. of America shares are owned by insiders. Comparatively, 4.8% of LHC Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Laboratory Co. of America and LHC Group's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Laboratory Co. of America$11.55 billion2.05$823.80 million$11.3221.52
LHC Group$2.08 billion2.78$95.73 million$4.4740.93

Laboratory Co. of America has higher revenue and earnings than LHC Group. Laboratory Co. of America is trading at a lower price-to-earnings ratio than LHC Group, indicating that it is currently the more affordable of the two stocks.

Summary

Laboratory Co. of America beats LHC Group on 9 of the 14 factors compared between the two stocks.


Laboratory Co. of America Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Quest Diagnostics logo
DGX
Quest Diagnostics
1.9$118.56+1.7%$15.82 billion$7.73 billion14.66
DaVita logo
DVA
DaVita
2.0$103.52+0.6%$11.33 billion$11.39 billion15.52
Amedisys logo
AMED
Amedisys
1.2$252.53+1.0%$8.30 billion$1.96 billion50.61Analyst Report
Insider Selling
Analyst Revision
R1 RCM logo
RCM
R1 RCM
1.6$28.06+0.8%$7.32 billion$1.19 billion311.76Insider Selling
Chemed logo
CHE
Chemed
2.5$441.96+0.9%$7.05 billion$1.94 billion26.80
LHC Group logo
LHCG
LHC Group
1.7$182.94+1.1%$5.78 billion$2.08 billion55.61Earnings Announcement
Analyst Revision
News Coverage
AMN Healthcare Services logo
AMN
AMN Healthcare Services
1.3$74.20+2.8%$3.49 billion$2.22 billion39.68Analyst Report
MEDNAX logo
MD
MEDNAX
1.4$25.01+2.0%$2.14 billion$3.51 billion-2.89
The Providence Service logo
PRSC
The Providence Service
1.0$133.59+5.2%$1.89 billion$1.51 billion-2,226.13
CorVel logo
CRVL
CorVel
0.8$102.66+2.9%$1.84 billion$592.22 million45.63Insider Selling
Tivity Health logo
TVTY
Tivity Health
1.0$23.17+1.5%$1.13 billion$1.13 billion-2.09Earnings Announcement
Analyst Upgrade
Analyst Revision
Cross Country Healthcare logo
CCRN
Cross Country Healthcare
1.1$11.29+5.0%$423.52 million$822.22 million-21.71Analyst Revision
Interpace Biosciences logo
IDXG
Interpace Biosciences
1.9$4.37+30.4%$17.93 million$24.08 million-0.52Insider Buying
Increase in Short Interest
Gap Down
This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.